/AKAN
AKAN Stock - Akanda Corp.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$0.61-10.42%
$0.07 (-10.42%) • Dec 19
45
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.54
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AKAN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.61 – $0.62
TARGET (TP)$0.71
STOP LOSS$0.56
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.65
52W High$9.29
52W Low$0.59
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $836,664 | $2.16M | $2.62M | $41,431 | $2,062 |
| Gross Profit | $208,382 | $111,449 | $3.27M | $-714,726 | $253 |
| Gross Margin | 24.9% | 5.2% | 124.8% | -1725.1% | 12.3% |
| Operating Income | $-4,382,482 | $-10,051,373 | $-20,176,389 | $-2,570,151 | $-1,665,835 |
| Net Income | $-4,096,029 | $-32,275,070 | $-11,657,674 | $-8,131,197 | $-2,300,571 |
| Net Margin | -489.6% | -1494.2% | -445.0% | -19625.9% | -111569.9% |
| EPS | $-3.93 | $-60.91 | $4.59 | $-127.66 | $-40.77 |
Company Overview
Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products in the United Kingdom, Lesotho, and internationally. It intends to supply cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
AKANBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.97
Q4 2021
EPS Surprise History
Q4 20
No data
Q3 21
No data
Q4 21
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2023 | Aug 7, 2023 | — | — | — | — |
Q2 2023 | May 1, 2023 | — | — | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.97 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-1.67 | — | — |
Q4 2020 | Dec 31, 2020 | — | $0.21 | — | — |
Latest News
U.S. Centers For Medicare & Medicaid Services Administrator Says Millions Of Americans On Medicare To Become Eligible To Receive CBD As Early As April
📈 PositiveBenzinga•Dec 18, 2025, 06:59 PM•Also: , ,
Trump Order Will Direct Maintaining Restrictions On Dangerous Products; Centers For Medicare & Medicaid Services Plans To Allow Beneficiaries To Benefit From Hemp-derived Cbd Products At No Cost; Trump Order Will Not Encourage Use, But Recognizes Potential Both Therapeutic Uses And Risks Like Addiction; Marijuana Will Remain Illegal To Possess Under Federal Law; Trump Order Makes No Changes To Criminal Penalties Or Access For Recreational Use Of Marijuana
➖ NeutralBenzinga•Dec 18, 2025, 06:51 PM•Also: , ,
Trump To Sign Executive Order On Thursday Aiming To Expedite Reclassification Of Marijuana As Schedule III Substance; Trump Order Will Allow More Research Of Medical Marijuana And Cannabidiol; Trump Order Will Help U.s. To Better Understand Risks Associated With Marijuana; There Is Currently Insufficient Evidence Of Marijuana's Medical Uses; Trump Order Will Direct White House To Work With Congress To Improve Access To Hemp-Derived CBD Products
📈 PositiveBenzinga•Dec 18, 2025, 06:49 PM•Also: , ,
'Trump's Marijuana Executive Order Details Leaked Ahead Of Announcement, Including CBD And Hemp Provisions'- Marijuana Moment
📈 PositiveBenzinga•Dec 18, 2025, 05:50 PM•Also: , ,
'Trump's Marijuana Rescheduling Order Could Include Industry Banking And CBD Medicare Coverage Provisions, Sources Say;'- Marijuana Moment
📈 PositiveBenzinga•Dec 17, 2025, 05:01 PM•Also: , ,
Shares of cannabis-linked stocks are trading higher following reports suggesting President Trump will sign an executive order that will reclassify marijuana to a Schedule III drug.
📈 PositiveBenzinga•Dec 17, 2025, 02:38 PM•Also: , ,
Shares of cannabis-linked stocks are trading higher after President Donald Trump confirmed his administration is strongly considering reclassifying marijuana.
📈 PositiveBenzinga•Dec 16, 2025, 07:17 PM•Also: , ,
Liz Claman Posts On X "ALERT: Word is a @realDonaldTrump executive order to reclassify cannabis/marijuana as less dangerous, less regulated Class III substance
📈 PositiveBenzinga•Dec 15, 2025, 08:48 PM•Also: , ,
President Trump Says Considering Executive Oder To Reclassify Marijuana
➖ NeutralBenzinga•Dec 15, 2025, 08:45 PM•Also: , ,
Shares of cannabis-linked stocks are trading higher following a report suggesting that President Trump is expected to reclassify marijuana as a Schedule III drug.
📈 PositiveBenzinga•Dec 12, 2025, 01:23 PM•Also: , ,
'Nebraska Supreme Court Hears Case Seeking To Overturn Medical Marijuana Law Approved By Voters' - Marijuana Moment
➖ NeutralBenzinga•Dec 4, 2025, 01:59 PM•Also: , ,
UPDATE: 'Medicare to Test Making CBD Treatment Available for Seniors' - Bloomberg News
📈 PositiveBenzinga•Nov 26, 2025, 05:58 PM•Also: , ,
'Marijuana Banking Bill Is 'On The Back Burner,' As Congressional Lawmakers See No Indication It'll Advance Soon' - Marijuana Moment
📉 NegativeBenzinga•Nov 25, 2025, 03:27 PM•Also: , ,
'GOP Representative Brian Mast Signs On As Sponsor Of Bipartisan Legislation To Reschedule Cannabis' - Marijuana Herald
📈 PositiveBenzinga•Nov 24, 2025, 04:19 PM•Also: , ,
Akanda Is Researching Security Requirements And Next Steps For A Full Cultivation License Through Its Cannabis Operating Subsidiary
📈 PositiveBenzinga•Nov 13, 2025, 09:29 PM
Akanda Has Furthered Its Cannabis Investment By Extending Its Option On Its British Columbia Asset For 2 Additional Years
📈 PositiveBenzinga•Oct 20, 2025, 12:09 PM
Akanda's First Towers & Fiber Unit To Construct Or Purchase Up To 20 Additional Towers By 2025 End To Expand Mexican Footprint
📈 PositiveBenzinga•Oct 20, 2025, 12:08 PM
Market-Moving News for October 17th
➖ NeutralBenzinga•Oct 17, 2025, 11:27 AM•Also: ,
Akanda shares are trading higher after the company announced it will construct or acquire up to 20 new or existing tower and sites by the end of 2025.
📈 PositiveBenzinga•Oct 16, 2025, 08:32 PM
Akanda And Subsidiary First Towers & Fiber To Construct Or Acquire 20 New Or Existing Towers/Sites By End Of 2025
📈 PositiveBenzinga•Oct 16, 2025, 08:31 PM
Frequently Asked Questions about AKAN
What is AKAN's current stock price?
Akanda Corp. (AKAN) is currently trading at $0.61 per share. The stock has moved -10.42% today.
What is the analyst price target for AKAN?
No analyst price targets are currently available for this stock.
What sector is Akanda Corp. in?
Akanda Corp. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is AKAN's market cap?
Akanda Corp. has a market capitalization of $0.00 billion, making it a small-cap company.
Does AKAN pay dividends?
No, Akanda Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBBLG
Bone Biologics Corporation
$1.83
Mkt Cap: $0.0B
GCTK
GlucoTrack, Inc.
$4.74
Mkt Cap: $0.0B
GNPX
Genprex, Inc.
$2.13
Mkt Cap: $0.0B
HSCS
HeartSciences Inc.
$2.36
Mkt Cap: $0.0B
IMCC
IM Cannabis Corp.
$1.56
Mkt Cap: $0.0B
JAGX
Jaguar Health, Inc.
$1.17
Mkt Cap: $0.0B
PRFX
PainReform Ltd.
$0.88
Mkt Cap: $0.0B
RDHL
RedHill Biopharma Ltd.
$1.18
Mkt Cap: $0.0B
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
$1.72
Mkt Cap: $0.0B
UPC
Universe Pharmaceuticals Inc.
$3.73
Mkt Cap: $0.0B
Explore stocks similar to AKAN for comparison